Business Context and Reporting Period
This Form 8-K Current Report was filed by Neumora Therapeutics, Inc. on February 13, 2025, regarding significant leadership changes and equity compensation adjustments effective February 14, 2025. The company is a biopharmaceutical entity incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol NMRA.
Key Financial Metrics and Compensation
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it details specific executive compensation adjustments and equity grants:
- Joshua Pinto, Ph.D. (New President): Annual base salary increased to $645,000; target annual bonus of 60% of base; one-time signing bonus of $970,000 (subject to clawback); granted option to purchase 3,000,000 shares vesting over four years.
- Bill Aurora, Pharm.D. (New Chief Operating and Development Officer): Annual base salary increased to $545,000; target annual bonus of 50% of base; one-time signing bonus of $860,000 (subject to clawback); granted option to purchase 1,000,000 shares vesting over four years.
- Michael Milligan (New Chief Financial Officer): Annual base salary increased to $450,000; target annual bonus of 40% of base.
Material Changes Versus Prior Period
The filing reports a comprehensive restructuring of the executive leadership team:
- CEO Transition: Paul L. Berns transitions from Executive Chairman to Chief Executive Officer and Chairman of the Board. Henry Gosebruch departs the company and the Board, no longer serving as President or CEO.
- Executive Promotions: Joshua Pinto moves from CFO to President; Michael Milligan moves from Principal Accounting Officer to CFO; Bill Aurora moves from Chief Strategy Officer to Chief Operating and Development Officer; Carol Suh moves from Chief Operating Officer to Chief Strategy Officer; Jason Duncan assumes the role of Chief Legal and Administrative Officer.
- Departures: Kaya Pai Panandiker departs as Chief Commercial Officer.
- Equity Repricing: The Board approved a contingent option repricing for eligible service providers (excluding Mr. Gosebruch). If approved by stockholders, the exercise price of underwater options will be reduced to the closing stock price on February 13, 2025, provided the provider remains employed through August 13, 2026.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or operational outlook. Key contingencies and risks include:
- Stockholder Approval: The option repricing is contingent upon stockholder approval. If not approved, the repricing is void, and original exercise prices remain in effect.
- Clawback Provisions: The one-time signing bonuses for Dr. Pinto and Dr. Aurora are subject to clawback if they terminate employment prior to August 13, 2026.
- Retention Risk: The repricing is designed to restore incentives for service providers to remain with the company; failure to retain key personnel could impact operations.
Important Facts for Investor Verification
- Verify the outcome of the stockholder vote regarding the option repricing, as this determines the final cost basis for executive equity.
- Confirm the total cash outflow for the immediate signing bonuses ($1.83 million combined for Pinto and Aurora) and its impact on current liquidity.
- Review the full text of the new Executive Employment Agreements (to be filed in the 2024 Form 10-K) for additional termination provisions or severance details.
- Assess the strategic rationale for the leadership shuffle, specifically the return of Co-Founder Paul Berns to the CEO role.